Pharmaids Pharmaceuticals Limited Stock Price Today (NSE: PHARMAID)

Pharmaids Pharmaceuticals Limited

34.501.00 (2.82%)
Market Closed

Fundamental Score

...

Pharmaids Pharmaceuticals Limited Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Pharmaids Pharmaceuticals Limited share price today is 34.50, down 2.82% on NSE/BSE as of 7 August 2026. Pharmaids Pharmaceuticals Limited (PHARMAID) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 119.13 (Cr). The 52-week high for PHARMAID share price is 68.00 and the 52-week low is 25.60. The company has a Return on Equity (ROE) of -26.51% and a debt-to-equity ratio of 0.49.

Pharmaids Pharmaceuticals Limited Share Price Chart — NSE/BSE Historical Performance

No data
High
41.90
Low
29.12
Volume
10.7K
Change
-15.44%

Pharmaids Pharmaceuticals Limited share price chart: -15.44% return over the past month. 52-week high ₹68.00, 52-week low ₹25.60.

Pharmaids Pharmaceuticals Limited — Last 10 Trading Days

DateOpenHighLowCloseVolume
36.2036.2034.0034.5010.34K (Cr)
33.1436.0433.0535.5054.16K (Cr)
31.9433.9030.1732.203.71K (Cr)
33.4433.4431.5032.517.64K (Cr)
33.9833.9831.0531.679.70K (Cr)
31.0031.8829.5531.001.88K (Cr)
29.5131.7929.5030.783.59K (Cr)
31.9031.9029.6630.302.21K (Cr)
31.1031.8529.5330.021.58K (Cr)
31.4031.8530.0530.493.72K (Cr)

Pharmaids Pharmaceuticals Limited — Last 12 Months Price History

MonthOpenHighLowCloseChange
33.9836.2030.1734.50+1.53%
41.9041.9029.1231.00-26.01%
30.9041.2525.6038.97+26.12%
30.2633.8027.2630.34+0.26%
27.9035.0027.9029.67+6.34%
31.8939.3027.1027.67-13.23%
40.6044.0030.0031.44-22.56%
47.6650.9040.9941.53-12.86%
46.9053.9043.3047.66+1.62%
48.6552.9743.0545.98-5.49%
58.0160.7942.0049.51-14.65%
62.8966.0053.7559.46-5.45%

Returns & Performance

Poor

Return on Equity (ROE)

-26.51%

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-18.52%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-58.01%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Pharmaids Pharmaceuticals Limited Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

32.99%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

56.88%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

50.52%

Revenue growth vs same quarter last year

Revenue Growth (5-Year CAGR)

N/A

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Average

Debt to Equity Ratio

0.49x

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-4.38x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-54.48 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Pharmaids Pharmaceuticals Limited Fundamental Analysis & Valuation Benchmarking

Educational evaluation of PHARMAID across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Robust Profit Growth (56.88%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (50.52%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

6 factors identified

Below-Average Return on Equity (-26.51%)

Observation: Returns on equity are below industry benchmarks.

Analysis: ROE <10% may indicate inefficient capital utilization. Consider monitoring for operational improvements and management effectiveness.

Suboptimal ROCE (-18.52%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-58.01%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Weak Interest Coverage (-4.38x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Negative Free Cash Flow (₹-54.48 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Pharmaids Pharmaceuticals Limited vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Pharmaids Pharmaceuticals Limited with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
18/100
35
₹119.13
-26.51%
Poor
-18.52%
Poor
0.5
Excellent
0.00%
66.4/100
1991
₹468821.49
37.7
Average
15.95%
Good
20.53%
Excellent
0.1
Excellent
16.75%
Excellent
11.78%
Good
0.82%
56.3/100
8056
₹193163.97
73.6
Average
16.53%
Good
21.96%
Excellent
0.0
Excellent
5.71%
Good
8.67%
Good
0.41%
51.4/100
5123
₹169902.02
77.5
Average
27.43%
Excellent
15.19%
Good
1.8
Average
12.07%
Good
11.80%
Good
0.76%
Cipla Ltd...
CIPLA500087
40.2/100
1473
₹116131.81
30.5
Average
11.60%
Average
15.49%
Good
0.0
Excellent
9.94%
Good
8.01%
Good
0.90%
74.1/100
1078
₹115375.77
21.3
Average
21.25%
Excellent
21.14%
Excellent
0.5
Excellent
18.77%
Excellent
12.45%
Good
0.09%
Lupin Ltd...
LUPIN500257
83.4/100
2415
₹113976.53
20.0
Average
28.68%
Excellent
29.93%
Excellent
0.3
Excellent
37.02%
Excellent
13.02%
Good
0.72%
61.5/100
2470
₹105053.91
52.3
Average
13.12%
Average
13.50%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%
41/100
1148
₹102660.46
25.6
Average
11.22%
Average
13.04%
Average
0.2
Excellent
15.44%
Excellent
12.09%
Good
0.65%
24.6/100
1580
₹90035.87
25.4
Average
10.06%
Average
12.80%
Average
0.2
Excellent
0.80%
Average
6.32%
Good
0.26%
34.1/100
1816
₹84016.75
93.9
Average
18.30%
Good
17.76%
Good
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%

Pharmaids Pharmaceuticals Limited Quarterly Performance

Latest quarterly metrics for PHARMAID — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

50.52%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

56.88%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

N/A

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Pharmaids Pharmaceuticals Limited Technical Indicators

SMA 50, SMA 200, RSI and volume signals for PHARMAID — calculated from daily price history

33RSI 14
Neutral — RSI 33

Momentum is balanced — neither overbought nor oversold.

SMA 50
32
▲ Price above SMA 50 — Short-term bullish
SMA 200
39
▼ Price below SMA 200 — Long-term downtrend
30-Day Avg Volume
18K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Pharmaids Pharmaceuticals Limited Financial Statements

Annual income statement, balance sheet and cash flow for Pharmaids Pharmaceuticals Limited (PHARMAID) — sourced from NSE/BSE filings.

Loading Financial Statements...

Fetching financial data for Pharmaids Pharmaceuticals Limited

About PHARMAID (Pharmaids Pharmaceuticals Limited)

Pharmaids Pharmaceuticals Limited is a dynamic and innovative force within the global pharmaceutical landscape, dedicated to pioneering advancements in healthcare through cutting-e...dge research, development, and manufacturing. With an unwavering commitment to improving patient lives, Pharmaids leverages its state-of-the-art facilities and a team of highly skilled scientists and engineers to create a diverse portfolio of high-quality pharmaceutical products. The company's core values revolve around integrity, quality, and innovation, driving its relentless pursuit of excellence in every aspect of its operations. Pharmaids's strong emphasis on research and development allows it to stay at the forefront of emerging therapeutic areas and deliver innovative solutions to unmet medical needs. At the heart of Pharmaids' operations lies a dedication to meeting the evolving needs of its customers and partners. The company boasts a comprehensive suite of services, encompassing custom synthesis, process development, and large-scale manufacturing. Pharmaids' commitment to quality is evident in its adherence to stringent regulatory standards and its implementation of robust quality control measures throughout the manufacturing process. With a global reach, Pharmaids serves a diverse clientele, including leading pharmaceutical companies, research institutions, and healthcare providers. Its collaborative approach and customer-centric focus ensure that its partners receive tailored solutions that meet their specific requirements, driving mutual success and long-term partnerships. Pharmaids Pharmaceuticals Limited distinguishes itself through its unwavering focus on sustainability and social responsibility. The company is committed to minimizing its environmental impact through the implementation of eco-friendly practices and the responsible use of resources. Pharmaids also actively engages in community outreach programs, supporting initiatives that promote health and education in underserved populations. By integrating sustainability and social responsibility into its core business practices, Pharmaids strives to create a positive impact on both the environment and the communities in which it operates. This commitment reflects the company's belief that business success and social progress are intrinsically linked.

Company Details

Symbol:PHARMAID
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Mr. B.C Balagangadhara
Chief Financial Officer
Mr. Prasanna Subramanya Bhat
Company Secretary & Compliance Officer
Mr. Venu Madhava Kaparthy
Executive Director

PHARMAID Share Price: Frequently Asked Questions

What is the current share price of Pharmaids Pharmaceuticals Limited?

Pharmaids Pharmaceuticals Limited (PHARMAID) trades at ₹34.50 on NSE and BSE. Market cap ₹119.13 (Cr). Educational data only.

What is the P/E ratio of Pharmaids Pharmaceuticals Limited?

Pharmaids Pharmaceuticals Limited has a P/E of N/Ax vs industry average 34.89x.

What is the Bull Run score for Pharmaids Pharmaceuticals Limited?

Pharmaids Pharmaceuticals Limited has a Bull Run score of 18/100 based on 25+ financial parameters.

Does Pharmaids Pharmaceuticals Limited pay dividends?

Pharmaids Pharmaceuticals Limited has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Pharmaids Pharmaceuticals Limited?

Pharmaids Pharmaceuticals Limited has ROE of -26.51%. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Pharmaids Pharmaceuticals Limited?

Pharmaids Pharmaceuticals Limited has debt-to-equity of 0.49.

Is Pharmaids Pharmaceuticals Limited a good investment?

Bull Run gives Pharmaids Pharmaceuticals Limited a score of 18/100. This is not investment advice — consult a SEBI-registered advisor.